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ABSTRACT
Background    Recent rapid advances in molecular 
biology have led the discovery of disease-specific novel 
fusion genes in a variety of soft tissue tumors. In this 
study, we attempted to detect these fusion genes using 
formalin-fixed paraffin-embedded (FFPE) tumor tissues 
and investigated their clinical utility and factors that 
affect the results of examination.
Methods    Reverse transcription polymerase chain 
reaction for the detection of tumor-specific fusion genes 
was performed using 41 FFPE tumor samples obtained 
from 37 patients representing nine histological types 
of soft tissue tumors that were diagnosed from 2006 to 
2017 in our laboratory.
Results    Fusion genes in 19 (51.3%) out of 37 cases 
were detected successfully. Relatively high detection 
rates were observed in synovial sarcomas (100%, 4/4) 
and alveolar rhabdomyosarcomas (75%, 3/4). The de-
tection rates of fusion genes were inversely correlated 
with the storage period of FFPE blocks. Decalcification 
by Plank-Rychlo solution significantly affected detec-
tion rates of the internal control gene (P = 0.0038). In 
contrast, there was no significant difference in detection 
rates between primary and metastatic lesion, or biopsy 
and resection material, or presence and absence of treat-
ment history.
Conclusion    In certain histological types, detection 
of disease-specific fusion genes of soft tissue tumors 
using FFPE tissues showed high sensitivity and thus had 
diagnostic utility. However, due to the diversity of fusion 
patterns and the low-quality of nucleic acid, the detec-
tion rate as a whole was sluggish and required further 
improvement. For factors affecting the detection results, 
our results suggested that it was impossible to detect 
fusion genes by decalcified FFPE tissues, but it may 
be not necessary to consider factors such as the type of 
specimen (biopsy or resection) and treatment history of 
the patients when selecting the FFPE tissues.
Key words    fusion gene; reverse transcription poly-
merase chain reaction; soft tissue tumor
Soft tissue tumors are a heterogeneous group of mesen-
chymal neoplasms which its histological assessment is 
challenging, as the morphology and immunoprofile of 
different tumor types frequently overlap, and can mimic 
other tumor types. So far, in the diagnosis of several 
sarcomas such as Ewing sarcoma or Synovial sarcoma, 
disease-specific fusion gene detection is useful.1–4 
Currently rapid molecular biological progress discovers 
novel fusion genes. Clinicopathological disease units 
of some sarcomas have been classified based on their 
genetic abnormalities.5 However, regarding the detection 
of translocation in such sarcomas, there are many types 
of translocation patterns, and optimization of standard 
methods for primer designs and reverse transcription 
polymerase chain reaction (RT-PCR) conditions have not 
been established, so it is not sufficiently clarified how 
much fusion gene detection contributes to improvement 
of diagnostic accuracy in the hospitals. In this study, 
we have searched fusion genes from soft tissue tumors, 
examined the diagnostic usefulness and evaluated how 
much it contributed to improvement of pathological 
diagnostic accuracy in general hospitals. At the same 
time, very important factors influencing detection of the 
fusion genes were also investigated from the standpoint 
of clinical laboratory technologist. 
MATERIALS AND METHODS 
Tumor Samples
We identified 37 cases of soft tissue tumors diagnosed be-
tween 1 April 2006 and 30 October 2017 with formalin-
fixed paraffin-embedded (FFPE) tissue available in 
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Table 1. Tumor tissue types and fusion gene detection results of all samples
Sample 
no.
Age of 
block
(in years)
Histological
diagnosis
Patient age
(in years) Gender Specimen Decalcification Translocation
Fusion point
(exon–exon) ACTB
1 5 SS 63 M excision – SYT-SSX2 9–7 Positive
2 2 SS 51 F excision – SYT-SSX1 9–7 Positive
3 0 SS 38 F excision – SYT-SSX2 9–7 Positive
4 0 SS 60 M biopsy – SYT-SSX1 9–7 Positive
5 11 ES 36 F excision + Negative Failed
6 8 ES 52 F biopsy – Negative Positive
7 4 ES 10 F biopsy – Negative Positive
8* 2 ES 47 F excision – Negative Positive
9* 0 ES 48 F excision – EWSR1-FLI1 7–5 Positive
10* 0 ES 6 F excision – EWSR1-FLI1 7–5 Positive
11* 0 ES 6 F excision + Negative Failed
12 0 DSRCT 43 M excision – EWSR1-WT1 9–8 Positive
13 4 MCS 35 F biopsy – Negative Positive
14* 1 MCS 67 F biopsy – HEY1-NCOA2 4–13 Positive
15* 1 MCS 67 F excision – HEY1-NCOA2 4–13 Positive
16 3 AFH 43 M excision – Negative Positive
17 8 EHE 28 F excision – Negative Positive
18 2 EHE 77 M excision – Negative Positive
19 3 MLPS 58 F excision – FUS-DDIT3 5–2 Positive
20 3 MLPS 63 M excision – FUS-DDIT3 5–2 Positive
21 7 MLPS 59 F excision – Negative Positive
22 8 MLPS 82 F biopsy – Negative Positive
23* 0 MLPS 49 M excision – FUS-DDIT3 5–2 Positive
24* 0 MLPS 49 M excision + Negative Failed
25 10 SFT 63 M excision – Negative Positive
26 5 SFT 79 F excision – Negative Positive
27 3 SFT 52 F excision – Negative Failed
28 3 SFT 54 F excision – Negative Positive
29 3 SFT 83 F excision – NAB2-STAT6 4–2 Positive
30 3 SFT 78 M excision – NAB2-STAT6 6–17 Positive
31 2 SFT 56 F excision – Negative Positive
32 2 SFT 60 F excision – NAB2-STAT6 4–2 Positive
33 1 SFT 71 F excision – NAB2-STAT6 6–17 Positive
34 0 SFT 70 M excision – Negative Positive
35 0 SFT 48 F excision – Negative Positive
36 0 SFT 63 M excision – NAB2-STAT6 4–2 Positive
37 0 SFT 58 F excision – Negative Positive
38 11 ARMS 16 F excision – PAX3/7-FOXO1 7–2 Positive
39 6 ARMS 74 F excision – Negative Failed
40 5 ARMS 7 M biopsy – PAX3/7-FOXO1 7–2 Positive
41 0 ARMS 9 M biopsy – PAX3/7-FOXO1 7–2 Positive
*8 and 9, or 10 and 11, or 14 and 15, or 23 and 24 are the same patients.
AFH, Angiomatoid fibrous histiocytoma; ARMS, Alveolar rhabdomyosarcoma; DSRCT, Desmoplastic small round cell tumor; EHE, 
Epithelioid hemangioendothelioma; ES, Ewing sarcoma; F, Female; M, Male; MCS, Mesenchymal chondrosarcoma; MLPS, Myxoid 
liposarcoma; SFT, Solitary fibrous tumor; SS, Synovial sarcoma. 
117
Detection of fusion genes from soft tissue tumors
Tottori University Hospital (Table 1). All of 37 cases 
were reassessed by a pathologist (S.K.) and the diagno-
ses were confirmed based on histological and immuno-
histochemical evaluation. In some cases, there were both 
biopsy and resection specimens, with some specimens 
being decalcified by Plank-Rychlo solution, and thus a 
total of 41 FFPE samples were available. Sample 8 and 9, 
or 10 and 11, or 14 and 15, or 23 and 24 were those from 
the same patients, respectively (Table 1). The diagnosis 
of the 37 cases (41 samples) was as follows; 4 (4 sam-
ples) synovial sarcoma, 5 (7 samples) Ewing sarcoma, 
1 (1 sample) desmoplastic small round cell tumor, 2 (3 
samples) mesenchymal chondrosarcoma, 1 (1 sample) 
angiomatoid fibrous histiocytoma, 2 (2 samples) epi-
thelioid hemangioendothelioma, 5 (6 samples) myxoid 
liposarcoma, 13 (13 samples) solitary fibrous tumor and 
4 (4 samples) alveolar rhabdomyosarcoma (Table 1). The 
characteristics of all samples as follows: 8 biopsy and 33 
resection samples, 34 primary lesion and 7 metastatic 
lesion samples, and 33 samples without chemoradi-
ation treatment and 11 samples with chemoradiation 
treatment. There were 2 Ewing sarcoma samples and 
1 myxoid liposarcoma sample that were decalcified by 
Plank-Rychlo solution. All samples were fixed with 10% 
neutral buffer formalin. Conditions of formalin fixation 
are 24 hours in biopsy specimens and about 1 week in 
resection specimens without incision.
Primers and Reverse Transcription-PCR
The primers which were designed with amplicon 
length of 75-160 bp and amplicon Tm of 60 ± 3 °C were 
made using the NCBI Primer-BLAST tool (Table 2). 
RNA was extracted from FFPE tissues by PureLink 
FFPE Total RNA Isolation Kit (Invitrogen, Waltham, 
MA). Total RNA from each FFPE sample was used to 
synthesize the first-strand cDNA using ReverTra Ace 
qPCR RT Master Mix with gDNA Remover (TOYOBO, 
Osaka, Japan). The subsequent PCR was performed in a 
final reaction volume of 20 µL containing 10 U TaKaRa 
Ex Taq Hot Start Version (TaKaRa, Shiga, Japan), 2 µL 
cDNA, 1 µL gene specific forward primer and reverse 
primer. The following PCR conditions were used an ini-
tial denaturation at 94 °C for 4 minutes 30 seconds, 40 
cycles at 94 °C (30 seconds), 55 °C (30 seconds), 72 °C 
(30 seconds), and one final extension at 72 °C for 4 min-
utes 30 seconds. Because the amplified products could 
not be obtained in the preliminary experiment standard 
RT-PCR in the myxoid liposarcoma cases, semi-nested 
PCR method which was represented by two types 
forward primers (external and internal) and one type 
reverse primer was adopted. The amplification profile 
of the first-round PCR consisted of 40 cycles of denatur-
ation at 94 °C for 4 minutes 3 seconds, annealing at 55 
°C for 30 seconds, and extension at 72 °C for 4 minutes 
30 seconds. The second-round PCR was 2 µL of 5-fold 
diluted solution of the first-round PCR product as a tem-
plate with the following cycling condition: denaturation 
at 94 °C for 4 minutes 3 seconds, annealing at 55 °C 
for 30 seconds, and extension at 72 °C for 4 minutes 30 
seconds. PCR products were visualized on a 2% aga-
rose gel using ethidium bromide staining. Several cases 
which the amplification product could not be detected 
were used as designed primers for another translocation 
pattern. In some cases, we tried to improve the detection 
rate as much as possible. PCR products of several cases 
were sequenced with forward and reverse primers in the 
Applied Biosystems 3500xL Genetic Analyzer (Thermo 
Fisher Scientific, Waltham, MA). As a control for cDNA 
synthesis and sample quality, each sample was reverse 
transcribed and amplified for the housekeeper gene 
ACTB (98 bp). 6
Statistical Analyses
Fisher’s exact test (two-sided) was performed to compare 
categorical variables. Results were considered significant 
when P-values were less than 0.05. All statistical analy-
ses were conducted using the R ver. 3.3.2.
Ethical Approval
This study has been implemented since it was approved 
by the Institutional Review Board of Tottori University 
Hospital (research management number, G179).
RESULTS
Detection Results
Of the all 37 extracted cases (Table 1), fusion gene 
amplicons were obtained in 19 (51.3%) cases, and ACTB 
amplicons were obtained 34 (91.9%) cases, it indicated 
adequate RNA quality, except 3 decalcified samples. Of 
these 34 cases, fusion gene amplicons were obtained in 
19 (55.9%) cases. Of these 34 cases, the detection rate 
for each tissue type was 100% (4/4 cases) in synovial 
sarcoma, 50% (2/4) in Ewing sarcoma, 100% (1/1) 
in desmoplastic small round cell tumor, 50% (1/2) in 
mesenchymal chondrosarcoma, 0% (0/1) in angiomatoid 
fibrous histiocytoma, 0% (0/2) in epithelioid hemangio-
endothelioma, 60% (3/5) in myxoid liposarcoma, 42% 
(5/12) in solitary fibrous tumor and 100% (3/3) in alveo-
lar rhabdomyosarcoma (Fig. 1). 
 EWSR1ex7-WT1ex8 that detected in more than 80% 
of cases, the most common fusion gene in one desmo-
plastic small round cell tumor case,7, 8 was not detected, 
however we detected EWSR1ex9-WT1ex8 which was 
a rare translocation pattern (Fig. 2). In an angiomatoid 
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Table 2. The retrieved fusion gene and primer sequence 
Histological 
diagnosis Gene fusion
Forward primer
(5’ –3’)
Reverse primer
(5’ –3’)
Fusion point 
(exon–exon)
Size
(bp)
SS SYT-SSX1 CCAGCAGAGGCCTTATGGATA ACACTCCCTTCGAATCATTTTCG 9–7 77
SYT-SSX2 (same as above) GCACTTCCTCCGAATCATTTCCT 9–7 77
ES EWSR1-FLI1 CCAAGTCAATATAGCCAACAGAGC CATGTTATTGCCCCAAGCTCCTC 7–5 156
EWSR1-FLI1 (same as above) (same as above) 7–6 90
EWSR1-ERG (same as above) TCCAGGAGGAACTGCCAAAG 7–9 154
DSRCT EWSR1-WT1 CCAAGTCAATATAGCCAACAGAGC GTCTGAACGAGAAAACCTTCG 7–8 102
EWSR1-WT1 GAGGACGCGGTGGAATGG (same as above) 8–8 78
EWSR1-WT1 (same as above) (same as above) 8–9 116
EWSR1-WT1 (same as above) (same as above) 8–10 149
MCS HEY1-NCOA2 ATCCTGCAGATGACCGTGGA TGGTTTGGCAATAACCTGCC 4–13 104
AFH EWSR1-CREB1 CCAAGTCAATATAGCCAACAGAGC ACCCCATCGGTACCATTGTTAG 7–7 98
EWSR1-ATF1 (same as above) CTCCATCTGTGCCTGGACTTG 7–5 97
FUS-ATF1 CAGCAGAACCAGTACAACAGC (same as above) 5–5 109
EHE WWTR1-CAMTA1 CTCCACCCTGCCGTCAGTTC TGCAGGTCCACTTGATGCCA 4–8 91
WWTR1-CAMTA1 (same as above) GCGAGATGATGCGGTGTTTG 4–9 124
MLPS FUS-DDIT3 External:
TAATCCCCCTCAGGGCTATGG
Internal:
CAGCAGAACCAGTACAACAGC
TTCAGGTGTGGTGATGTATGAA 5–2 98
FUS-DDIT3 External:
TATGAACCCAGAGGTCGTGGA
Internal:
AAGTGACCGTGGTGGCTTC
(same as above) 7–2 75
FUS-DDIT3 (same as above) (same as above) 8–2 108
EWSR1-DDIT3 External:
ACTGGATCCTACAGCCAAGC
Internal:
CCAAGTCAATATAGCCAACAGAGC
(same as above) 7–2 86
SFT NAB2-STAT6 CTTGTCCTCCTTGAAGGGCTC TTTTTCTGGGGGCATCTTGGA 4–2 139
NAB2-STAT6 CAGCAGACACTGATGGACGAGG AGCTGGGACATAACCCCTGC 6–17 144
NAB2-STAT6 CAGCAGACACTGATGGACGAGG CTTTGGCAGAGAATGGCTGGATG 6–16 145
ARMS PAX3-FOXO1 CCCAGCACCAGGCATGGATTT GCTGTGTAGGGACAGATTATGACGA 7–2 138
PAX7-FOXO1 CTACGGAGCCCGCCACA (same as above) 7–2 136
AFH, Angiomatoid fibrous histiocytoma; ARMS, Alveolar rhabdomyosarcoma; DSRCT, Desmoplastic small round cell tumor; EHE, 
Epithelioid hemangioendothelioma; ES, Ewing sarcoma; MCS, Mesenchymal chondrosarcoma; MLPS, Myxoid liposarcoma; SFT, 
Solitary fibrous tumor; SS, Synovial sarcoma.
fibrous histiocytoma case, neither EWSR1ex7-CREB1ex7,9, 10 
EWSR1ex7-ATF1ex59–12 nor FUSex5-ATF1ex513, 14 was 
detected. In two epithelioid hemangioendothelioma cas-
es, no amplified products were obtained for WWTR1ex4-
CAMTA1ex8 (type1) and WWTR1ex4-CAMTA1ex9 
(type2).15, 16
Affectors of Detection
Factors affecting detection of fusion genes were exam-
ined. To investigate the effects of decalcification, we 
selected 2 samples of Ewing sarcoma and 1 sample of 
myxoid liposarcoma that were decalcified FFPE sam-
ples. No amplified products either transcription or ACTB 
were detected in these samples (Fig. 3). Therefore, in the 
subsequent examination, affectors other than decalcifi-
cation were analyzed in the FFPE samples excluding the 
decalcified samples. FFPE tissues stored at room tem-
perature have been used as archival resources in many 
molecular studies. The characteristic of FFPE samples 
based on storage period as follows: less than one year 
(11 samples), one to two years (8 samples), three to four 
years (9 samples), five to seven years (5 samples), and 
eight to eleven years (5 samples). The detection rates for 
fusion genes were as follows; 73% (8/11) for samples 
stored less than one year was positive, 63% (5/8) for 
samples stored one to two years was positive, 44% (4/9) 
for samples stored three to four years was positive, 40% 
(2/5) for samples stored five to seven years was positive, 
and 20% (1/5) for samples stored eight to eleven years. 
As described above, the longer the storage period, the 
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lower the detection rates of fusion transcripts will be. 
Whereas the detection rates for ACTB were as follows; 
100% (11/11) for samples stored less than one year was 
positive, 100% (8/8) for samples stored one to two years 
was positive, 89% (8/9) for samples stored three to four 
years was positive, 80% (4/5) for samples stored five to 
seven years was positive, and 100% (5/5) for samples 
stored eight to eleven years was positive. As described 
above, the detection rates were almost constant re-
gardless of the storage period (Fig. 4). There was no 
significant difference in the detection rates of the fusion 
genes and ACTB, between biopsy and resection samples 
(Fig. 5A), between with and without chemoradiation 
treatment samples (Fig. 5B), and between primary lesion 
and metastatic lesion samples (Fig. 5C).
DISCUSSION
Even though the frequency of each histological types of 
soft tissue tumors are rare, there are over 100 types of 
histological type.5 In addition, we recognize general his-
topathological diagnosis limitations, as the morphology 
and immunoprofile of different tumor types frequently 
overlap and can mimic other tumor types. Furthermore, 
in recent years, with advances in treatments such as 
chemotherapy or radiation therapy, opportunities are 
increasingly demanded for definite diagnosis with a 
sample volume in minute amounts by preoperative 
needle biopsy. The detection of tumor-specific fusion 
genes is becoming an integral part of the diagnostic 
investigation of soft tissue tumors. In more detail, syno-
vial sarcoma showing from epithelial to sarcoid lesion 
may cause diagnostic challenges. However, detecting 
disease-specific fusion genes such as SYT-SSX1 or SYT-
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Fig. 1. The detection rates of fusion genes for each tissue types 
with ACTB negative cases exclusion. *Number of fusion gene 
detection cases and total cases by tissue types. AFH, Angiomatoid 
fibrous histiocytoma; ARMS, Alveolar rhabdomyosarcoma; 
DSRCT, Desmoplastic small round cell tumor; EHE, Epithelioid 
hemangioendothelioma; ES, Ewing sarcoma; MCS, Mesenchymal 
chondrosarcoma; MLPS, Myxoid liposarcoma; SFT, Solitary 
fibrous tumor; SS, Synovial sarcoma. 
Fig. 2. DNA sequence analysis showing EWSR1ex9-WT1ex8 gene 
fusion of Desmoplastic small round cell tumor.
Fig. 3. The effect of decalcification for fusion genes and ACTB 
detection rates. **P < 0.01. N.S., not significant
SSX2 helps diagnosis of this tumor. Furthermore, in 
round cell sarcomas such as Ewing sarcoma or rhabdo-
myosarcoma, detecting the fusion genes are important 
for deciding course of treatment. One reason is that the 
patients suffering from tumors of specific subtypes of 
round cell sarcoma, like Ewing sarcoma or rhabdomyo-
sarcoma, respond to well-defined therapeutic regimens. 
Proper classification of soft tissue tumors is crucial for 
appropriate patient management. In this study, we have 
searched fusion genes from soft tissue tumors, exam-
ined the diagnostic usefulness and evaluated how much 
it contributed to improvement of pathological diagnostic 
accuracy in general foundation hospitals. At the same 
time, from the standpoint of clinical laboratory technol-
ogist, we also analyzed factors influencing the detection 
of fusion genes.
 In the cases of ACTB positive, the comprehensive 
detection rate was not as high as 55% (19/34 cases).  It 
has been suggested that one of the causes could be that 
primers of our own design may not cover all of the 
fusion genes that can be expressed in our soft tissue 
tumor cases because there are multiple types of fusion 
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Figure 5 Fig. 4. Comparison of fusion genes and ACTB detection rates based on FFPE storage period. FFPE, formalin-fixed paraffin-embedded; 
yr, year(s).
Fig. 5. Comparison of the detection rates of fusion genes and 
ACTB in each factor. N.S., not significant
genes or fusion points in soft tissue tumors. Focusing 
on the detection rate in each histological type, favorable 
detection results were obtained in synovial sarcoma 
and alveolar rhabdomyosarcoma. Tsuji et al. reported 
that the frequencies of the fusion genes SYT-SSX1 and 
SYT-SSX2 by RT-PCR in synovial sarcomas were 73% 
and 24% respectively,1 whereas PAX3-FOXO1 and 
PAX7-FOXO1 have been described in 55% and 22% of 
alveolar rhabdomyosarcomas, respectively, according to 
Sorensen et al.17 These two tissue types have high detec-
tion rates because the translocation pattern is relatively 
limited. On the other hand, angiomatoid fibrous histio-
cytoma and epithelioid hemangioendothelioma prove a 
challenge to detect translocations from FFPE samples 
by our designed primers and PCR condition. The reason 
why a sufficient detection rate could not be obtained in 
these tumors may be attributable to various translocation 
A
C
B
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pattern, in addition, to the RNA ravages due to storage 
time in the FFPE samples.
 The fusion genes in 5 myxoid liposarcoma cases 
were not detected by standard RT-PCR in preliminary 
experiment. It may be affected by the low concentration 
of the tumor cells. However, the fusion genes in 3 out 
of 5 cases in myxoid liposarcoma were successfully 
detected by semi-nested RT-PCR. Powers et al. report-
ed that fusion genes of myxoid liposarcoma could be 
efficiently detected by standard RT-PCR.18 On the other 
hand, Hisaoka et al. showed that the nested RT-PCR 
assay could specifically detect multiple consistent fusion 
gene transcripts of myxoid liposarcoma generated after 
splicing of introns in which most of the variable break-
points are located.19 As described above, the fusion gene 
retrieval from FFPE samples of this tumor is recom-
mended to use nested RT-PCR or semi-nested RT-PCR. 
In this study, fusion genes of myxoid liposarcoma could 
be detected sufficiently even with semi-nested RT-PCR.
We searched for EWSR1-FLI1, the most common fusion 
variant in Ewing sarcoma cases which has two type 
variants: type 1 (55%) and type 2 (25%), and the second 
common fusion variant was EWSR1-ERG (10%).2–4 The 
detection rate was 50% (2/4 cases). Next we evaluated 
NAB2-STAT6, the most common fusion gene variant 
in solitary fibrous tumor cases which had three type 
variants as follows: type 1 (45%), type 2 (21%), and type 
3 (21%).20 We found the detection rate for NAB2-STAT6 
was 42% (5/12 cases), which was not high. The detection 
rate in mesenchymal chondrosarcoma cases was 50% 
(1/2 cases), we could not obtain adequate result. The 
results described above seemed also being caused by the 
quality of FFPE samples or the variation of the fusion 
genes which influenced the detection rate.
 In this experiment, we adopted RT-PCR assay 
because Patel et al. state that RT-PCR targeting the spe-
cific fusion transcripts associated with soft tissue tumors 
are a valuable ancillary tool for diagnosis,16 particularly 
as more soft tissue tumors are discovered to harbor re-
current translocations involving overlapping genes. They 
also made the cautionary comment that fluorescence in 
situ hybridization alone may be unsuitable for evaluating 
different types of tumors sharing the same gene rear-
rangement.16
 We examined factors that affect in the search for 
fusion gene using FFPE samples, and as a result, the de-
calcification was the most influential factor. Primary and 
metastatic bone tumors decalcify during tissue pathol-
ogy specimen preparation process. Nam et al. showed 
that the PCR results were significantly affected by the 
decalcification time and the yield of RNA or DNA from 
decalcified tissues decreased gradually with increasing 
decalcification time.21 Therefore, for examining fusion 
gene from primary and metastatic bone tumor tissues, 
it is necessary to selectively cut out portions which not 
requiring decalcification process. In addition, when 
selecting FFPE blocks for genetic diagnosis, it is recom-
mended to use nondecalcified blocks.
 The detection rates of fusion genes also were greatly 
affected by the storage period of FFPE samples.21 In our 
study, even FFPE samples stored for one to two years 
showed lower detection rates than FFPE samples stored 
for less than one year, suggesting that deterioration of 
RNA is caused even for a storage period about one year 
depending on the case. Therefore, since an acceptable 
range was not established for the storage period of FFPE 
samples in which detection of the fusion gene is possi-
ble, it was considered to perform the detection as soon 
as possible.
 We compared the detection rates of fusion genes 
between biopsy and resection samples, but there was 
no significant difference. Detection using biopsy sam-
ples could have a false negative due to lack of sample 
volume. However, in this study, even taken from small 
quantities of specimens it is suggested that detection is 
possible as long as tumor components are sufficiently 
contained. Furthermore, it is considered that RNA is not 
easily influenced by RNase because the biopsy materials 
undergo formalin fixation completely in a short time. 
Therefore, it is possible that excellent detection results 
could be obtained despite a small amount of biopsy 
materials. In the approximately 1-week formalin-fixed 
resection specimens, the detection rates were high in 
ACTB despite being fixed in formalin without incision. 
This means that the influence that the fixed condition 
had on fusion gene detection was minimal. According to 
Nam et al., when conducting a gene search study from 
RNA, it is recommended using 20% formalin for tissue 
fixation and the tissues should be immersed in formalin 
solution for 3 to 7 days.21 In other words, to obtain a 
highly accurate result, it is important to quickly inacti-
vate RNase in the tissue. However, large resection speci-
mens require considerable time for completing formalin 
fixation step. In the fusion gene search using RT-PCR, 
it is recommended that a part of the tumor is collected 
and fixed from the surgically resected specimen before 
RNA is affected by RNase to ensure constant detection 
sensitivity.
 We also examined other factors that affect detection 
results. When comparing the detection rates between 
with and without chemoradiation treatment samples, or 
primary lesion and metastatic lesion samples, no signif-
icant difference was observed. Metastasis and chemora-
diation treatment could cause gene mutations in tumors, 
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these factors were thought affecting the detection rate, 
but in this study there were no differences among these 
factors. This may indicate that the fusion genes are like-
ly to be retained even in metastasis or after treatment. 
Therefore, it suggests that considering these factors as 
confounding factors in the fusion gene search might not 
be necessary. Our results may suggest that the soft tissue 
tumors are cancer stem cell derived tumors. Zhou et al. 
reported that the development of synovial sarcoma may 
arise from cancer stem cells.22 Furthermore, cancer stem 
cells show resistance to chemotherapy and radiotherapy 
which known as the cause of recurrence and metas-
tasis.23 In the light of above, our findings may suggest 
that soft tissue tumors used in this study are tumors that 
originated from cancer stem cells. To the best of our 
knowledge, there was no literature comparing the detec-
tion rates of fusion genes which collected from various 
conditions samples as in our study condition. However, 
since we analyzed only 41 samples, we consider that 
further examination is necessary to get more accurate 
results.
 The results obtained in this study, the storage peri-
ods or decalcification, were similar to the data reported 
by Kanai et al.24 However, these published data do not 
indicate how much they can respond to the routine work 
in general hospitals or data comparing the detection rates 
between primary and metastatic lesions, biopsy and re-
sected material, or the presence or absence of treatment 
history. In our study, it was indicated that the fusion 
genes of tumors showing relatively simple chromosomal 
abnormalities can be detected by selecting FFPE blocks 
with short-storage periods and nondecalcification even 
at general hospitals. Furthermore, it was indicated that 
factors such as biopsy or resected material, primary or 
metastatic lesions, or the presence or absence of treat-
ment history may not be necessary while considering 
selection of FFPE blocks.
 In recent years, rapidly developing genomic medi-
cine adds consideration how to handle and manage the 
pathological tissue samples storage properly. The quality 
control of FFPE samples is important in examinations 
using molecular pathological methods, since numerous 
factors could affect the detection of fusion genes. The 
quality control of FFPE samples, formalin fixation and 
decalcification conditions are becoming the clinical 
laboratory technologist’s responsibility who is involved 
in pathological examination. These parts will greatly 
affect gene search, therefore we need to ensure these ac-
curacies. Even more, we consider the same importance 
of how to handle pathological tissue samples focusing on 
genetic diagnosis as well as how to handle samples for 
histopathological and immunohistological diagnosis. At 
the same time, establishing optimal fixation conditions 
and standardizing methods for fusion gene search are 
essential for improving the accuracy of molecular patho-
logical diagnosis in pathology laboratory.
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